Patents Assigned to McLean Hospital Corporation
  • Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases
    Patent number: 8153422
    Abstract: Disclosed herein are methods for generating dopaminergic neurons in vitro by inhibiting a pathway component of a TGF-? signaling pathway and overexpressing one or more cell fate-inducing polypeptides in pluripotent cells, causing differentiation of the pluripotent cells into dopaminergic neurons. Also disclosed are methods for treating a neurodegenerative disease in a patient by generating dopaminergic neurons in vitro, and transplanting them into the brain of the patient, such that the dopaminergic neurons are sufficient to reduce or eliminate the symptoms of the neurodegenerative disease.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: April 10, 2012
    Assignee: The McLean Hospital Corporation
    Inventors: Ole Isacson, Lars Bjorklund
  • Methods and compositions for the treatment of Parkinson's Disease
    Patent number: 8114892
    Abstract: The invention features methods and kits for treating or inhibiting the development of Parkinson's Disease by administering 7-chloro-4-aminoquinoline compounds, e.g., amodiaquine or glafenine. Stem cells are also useful in the methods of the invention and may be administered separately from or together with 7-chloro-4-aminoquinoline compounds. The invention further features methods of identifying additional chemical compounds that are useful in the treatment or inhibition of the development of Parkinson's Disease.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: February 14, 2012
    Assignee: The McLean Hospital Corporation
    Inventors: Deog Joong Kim, Chun Hyung Kim, Kwang Soo Kim
  • Magnetic Field Treatment Techniques
    Publication number: 20120022315
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Application
    Filed: September 28, 2011
    Publication date: January 26, 2012
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • SALVINORIN DERIVATIVES AND USES THEREOF
    Publication number: 20120010219
    Abstract: The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.
    Type: Application
    Filed: December 14, 2009
    Publication date: January 12, 2012
    Applicant: The McLean Hospital Corporation
    Inventors: Cecile Beguin, Justin Stephen Potuzak, Thomas Anthony Munro, Katherine K. Duncan, William A. Carlezon, Bruce M. Cohen, Lee-yuan Liu Chen
  • Computerized methods for evaluating response latency and accuracy in the diagnosis of attention deficit hyperactivity disorder
    Patent number: 8078253
    Abstract: Provided are methods for diagnosing the presence, type, or severity of a dementia in a human subject. The methods involve using a computer-based system to assess impairment of certain cognitive and motor functions that are indicative of Alzheimer's disease and other forms of dementia.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: December 13, 2011
    Assignee: The McLean Hospital Corporation
    Inventors: Martin H. Teicher, Steven B. Lowen
  • METHODS AND SYSTEMS FOR DRUG SCREENING AND COMPUTATIONAL MODELING BASED ON BIOLOGICALLY REALISTIC NEURONS
    Publication number: 20110301856
    Abstract: A method for screening a test composition for potential efficacy in treatment of a disorder includes a first computer model representative of a volume of disease-afflicted neural tissue comprising biologically realistic neurons exposed to the test composition; and providing an initial excitation to the first computer model. Following a selected computation interval, a first outcome is determined. The first outcome indicates a response of the first computer model to the initial excitation and indicates whether the test composition has the potential to be effective in treating the disorder.
    Type: Application
    Filed: May 6, 2011
    Publication date: December 8, 2011
    Applicant: MCLEAN HOSPITAL CORPORATION
    Inventors: Peter Siekmeier, Steven Matthysse
  • R(?)-11-hydroxyaporphine derivatives and uses thereof
    Patent number: 8063060
    Abstract: The invention features derivatives of R(?)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: November 22, 2011
    Assignee: The McLean Hospital Corporation
    Inventors: John L. Neumeyer, Ross J. Baldessarini
  • Magnetic field treatment techniques
    Patent number: 8047979
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: November 1, 2011
    Assignee: McLean Hospital Corporation
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • Drug-Enhanced Neurofeedback
    Publication number: 20110263968
    Abstract: The present invention relates to techniques and systems for training a subject to modify his or her own neutronal activity within a selected brain region.
    Type: Application
    Filed: November 4, 2009
    Publication date: October 27, 2011
    Applicant: MCLEAN HOSPITAL CORPORATION
    Inventors: Elizabeth Quattrocki-Knight, Bruce Cohen
  • Compounds for the treatment of psychiatric or substance abuse disorders
    Patent number: 8030294
    Abstract: The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: October 4, 2011
    Assignee: The McLean Hospital Corporation
    Inventor: Perry F. Renshaw
  • METHOD AND APPARATUS FOR IDENTIFYING A SAFE AND EFFICACIOUS DOSING REGIMEN
    Publication number: 20110208437
    Abstract: The invention features methods and systems to provide, in one test session, information on the patient's sensitivity to a probe drug for treating attentional disorders. The methods and systems of the invention can enable clinicians and consumers to ascertain how much benefit an individual would derive from treatment, what dose would be required, and the acute effect of that dose on regularity and rhythmicity of their heartbeat.
    Type: Application
    Filed: July 31, 2009
    Publication date: August 25, 2011
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventor: Martin Teicher
  • METHODS FOR MEASURING THE MAGNITUDE OF ATTENTION AND MOTOR ACTIVITY DISTURBANCE IN A SUBJECT
    Publication number: 20110208439
    Abstract: The invention features methods and systems to monitor changes in the magnitude of attentional disturbance and the magnitude of motor activity disturbance in a subject. The invention also features methods and systems for determining a subject's degree of concordance with individuals having an attentional disorder versus individuals not having an attentional disorder. The methods and systems of the invention can enable clinicians and consumers to ascertain both the severity of an attentional disorder as well as how much an individual changes over time, or with therapy.
    Type: Application
    Filed: October 8, 2009
    Publication date: August 25, 2011
    Applicant: The McLean Hospital Corporation
    Inventor: Martin H. Teicher
  • Compounds for the treatment of marihuana dependence, withdrawal, and usage
    Patent number: 7947661
    Abstract: The invention provides methods for treating or suppressing marihuana usage, withdrawal, or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, uridine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: May 24, 2011
    Assignee: The McLean Hospital Corporation
    Inventors: Scott E. Lukas, Perry F. Renshaw
  • Method for determining fluctuation in attentional state and overall attentional state
    Patent number: 7942828
    Abstract: The invention provides methods for determining shifts in the attentional state of a subject. These methods are useful for diagnosing subjects with a psychological or behavioral disorder. The invention also features methods for determining the effect of a therapy on the overall attentional state and shifts in the attentional state of a subject.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: May 17, 2011
    Assignee: The McLean Hospital Corporation
    Inventors: Martin H. Teicher, Steven B. Lowen
  • Methods and systems for drug screening and computational modeling based on biologically realistic neurons
    Patent number: 7945392
    Abstract: A method for screening a test composition for potential efficacy in treatment of a disorder includes a first computer model representative of a volume of disease-afflicted neural tissue comprising biologically realistic neurons exposed to the test composition; and providing an initial excitation to the first computer model. Following a selected computation interval, a first outcome is determined. The first outcome indicates a response of the first computer model to the initial excitation and indicates whether the test composition has the potential to be effective in treating the disorder.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: May 17, 2011
    Assignee: McLean Hospital Corporation
    Inventors: Peter Siekmeier, Steven Matthysse
  • METHODS AND KITS FOR TREATING CLUSTER HEADACHE DISORDERS
    Publication number: 20110104275
    Abstract: The invention features methods and kits employing bromolysergide in therapies for the treatment of cluster headache disorders.
    Type: Application
    Filed: September 4, 2009
    Publication date: May 5, 2011
    Applicants: The McLEAN Hospital Corporation, Medizinische Hochschule Hannover
    Inventors: John H. Halpern, Torsten Harry Johannes Passie
  • R(-)-2-METHOXY-11-HYDROXYAPORPHINE AND DERIVATIVES THEREOF
    Publication number: 20110034446
    Abstract: The invention features derivatives of R(?)-2-methoxy-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
    Type: Application
    Filed: July 10, 2008
    Publication date: February 10, 2011
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: John L. Neumeyer, Yu-Gui Si
  • Methods for the treatment of mood disorders
    Patent number: 7884077
    Abstract: The invention features methods of treating mood disorders, such as manic disorders, and stabilizing moods by administering a kappa agonist or partial agonist to a subject in need thereof.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: February 8, 2011
    Assignee: The McLean Hospital Corporation
    Inventors: Bruce M. Cohen, Beth L. Murphy
  • METHODS AND COMPOSITIONS FOR MITOCHONDRIAL REPLACEMENT THERAPY
    Publication number: 20110008310
    Abstract: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.
    Type: Application
    Filed: May 2, 2008
    Publication date: January 13, 2011
    Applicant: The McLean Hospital Corporation
    Inventors: Anne M. Cataldo, Peter A. Paskevich, Bruce M. Cohen
  • Compounds for the treatment of psychiatric or substance abuse disorders
    Patent number: 7863254
    Abstract: The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: January 4, 2011
    Assignee: The McLean Hospital Corporation
    Inventor: Perry F. Renshaw